Metastasectomy and Surgical Resection of the Primary Tumor in Patients With Stage IV Breast Cancer : Time for a Second Look?

Barbara A. Pockaj MD, Nabil Wasif MD, Amylou C. Dueck PhD, Dennis A. Wigle MD, Judy C. Boughey MD, Amy C. Degnim MD, Richard J. Gray MD, Sarah A. McLaughlin MD, Donald W. Northfelt MD, Robert P. Sticca MD, James W. Jakub MD, Edith A. Perez MD
Breast Oncology
Volume 17, Issue 9 / September , 2010

View full article HTML | View full article PDF | Download Citation

Abstract

Patients with metastatic or stage IV breast cancer have limited therapeutic options, and the mainstay of treatment remains systemic chemotherapy. Traditionally, the role of surgery has been confined to strict palliation. Improvements in the efficacy of chemotherapeutic regimens, coupled with the use of hormonal and targeted therapy, have resulted in an expansion of surgical resection beyond simple palliation. Several single-institution studies have reported improved survival and even long-term cures after surgical resection for oligometastatic stage IV breast cancer. Similarly, provocative new data suggest that removal of the primary tumor in some patients may confer a survival advantage. The aim of this review is to summarize studies in the medical literature pertaining to the use of surgical resection in patients with stage IV breast cancer. We believe there is enough evidence to challenge conventional thinking about the role of surgery in stage IV breast cancer and to consider a new multimodality treatment paradigm to optimize patient outcomes. It is time to conduct a carefully designed randomized trial to see whether surgery in stage IV breast cancer does indeed warrant a second look.

Go to Issue Contents